Article Details
Retrieved on: 2022-06-13 20:30:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pfizer's TTI-622 is currently in Phase 1b/2 development across several indications, with a focus on hematological malignancies. CD47 is an innate ...
Article found on: www.pfizer.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here